If you’re a health and life sciences investor looking for your next market, the UK deserves a serious look. World-class science, diverse health data, and a government that’s actively promoting the sector with investment and meaningful reform.

The fundamentals are strong, the regulatory environment is improving at pace, and the capital flows are following. But understanding the market is just as important as recognising the opportunity, and the detail matters.

Strong foundations

The UK is already a global leader in life sciences. According to the Office for Life Sciences, the sector generated turnover of £125.8bn and employed more than 300,000 people in 2024/25. Put that alongside the activity of Oxford and Cambridge Universities and Imperial and University College London, and there is a strong pipeline of spinouts, translational research, and early-stage assets that are difficult to match elsewhere. The clustering effects in cities like London, Manchester and Edinburgh, where academic institutions, world-class hospitals, NHS or health networks, and innovation hubs converge, create an ecosystem that’s greater than the sum of its parts.

Then there’s the NHS, one of the world's largest publicly funded health systems. For international entrants, the NHS offers something valuable: a structured environment to demonstrate clinical effectiveness and generate real-world evidence at scale. It’s worth noting, however, that there’s no single national route to entering the NHS market. Commissioning and procurement vary significantly across organisations, and navigating that landscape requires careful planning and local knowledge.

Capital is paying attention

The government's 2025 Life Sciences Sector Plan attracted significant investment commitments from major industry players, and a July 2026 government report confirmed that more than £3bn in new public and private investment had been committed during the first year of the plan. That includes a £300m commitment from AstraZeneca to expand its Cambridge headquarters and support AI-driven drug discovery work in Macclesfield, and a £1bn UK research and development commitment from Moderna over ten years, anchored by a new innovation centre at Harwell.

The government's ambition is for the UK to become the third largest life sciences economy in the world by 2035. It’s an ambitious target, and one that investors will assess alongside practical market conditions.

An increasingly efficient regulatory environment

This is where the UK is differentiating itself from other major markets, and it’s worth understanding the specifics.

• ILAP: The Innovative Licensing and Access Pathway (ILAP) is one of the most integrated end-to-end access pathways available globally, where a medicine developer can work collaboratively with the NHS, the Medicines and Healthcare products Regulatory Agency (MHRA), and health technology assessment (HTA) bodies from the early stages of clinical development. The ILAP operates as a single, system-level partnership designed to support parallel, coordinated progress across regulatory approval, HTA review, and NHS adoption planning. For international developers used to navigating those processes sequentially and independently, it’s a meaningful and practical shift.
• Efficient regulatory submissions: Since leaving the EU, the MHRA has also moved to establish its own approval timelines independent of the European Medicines Agency (EMA) and is actively working to position the UK as a first-choice market for early regulatory submissions. In April 2026, the MHRA and the National Institute for Health and Care Excellence (NICE) launched a new aligned assessment pathway, designed to shorten access times by three to six months for eligible treatments. For international businesses that have historically defaulted to EMA approval as their route to UK market access, this is a material change worth factoring into your regulatory strategy.
• Faster clinical trials: The government has made cutting red tape in clinical research a clear priority. The median time to set up a commercial clinical trial fell to 100 days in the three months to March 2026, down from 153 days a year earlier, a significant improvement in speed and predictability that matters for international companies deciding where to run their trials.
• Health data at scale: Up to £600m from the government and Wellcome is being invested to build the Health Data Research Service (HDRS), giving researchers secure, streamlined access to NHS data spanning primary and secondary care, subject to appropriate data governance and safeguards. Initial delivery is planned for December 2026. Combined with the UK's uniquely comprehensive cradle-to-grave patient records and its diverse population, this is a data proposition difficult to replicate anywhere else in the world.

What we are seeing on the ground

We’re seeing a huge uptick in life sciences, med tech and healthcare providers looking at UK market entry. One of the trickiest areas they’re trying to navigate is securing market access to the NHS – both understanding entry points and the NHS standard terms and conditions that are used as the base for contracts. 

For healthcare providers, the Care Quality Commission (CQC) is the biggest hurdle, as any business providing regulated health and social care activities in England generally needs to register with the CQC before operating. Preparation should start early. That means getting the right building blocks in place ahead of time, including suitable premises where relevant, to support the application. This is one of the most common points of complexity we see for international entrants, and getting ahead of it early is essential.

Getting the entry right

We advise international healthcare providers, digital health businesses, and investors as they establish and scale their presence in the UK, and the pace of inbound activity over the past few years has been striking.

Getting the entry right matters. The right corporate structure, the right regulatory strategy, the right contractual foundations from the outset. These aren’t administrative details. They’re the difference between a UK presence that performs and one that gets bogged down in avoidable complexity.

Ready to enter the UK health market?

Learn more about Entering the UK health market, our structured legal services package designed to provide support at every stage of your market entry and establishment journey. From corporate set-up and CQC registration through to NHS contracting and MHRA regulation, our specialist health team can work with you across numerous workstreams, on a pick-and-mix or full-suite basis, with fixed fees and full cost transparency from day one.

If you’re considering entering the UK health market and want to understand what that looks like in practice, speak to our specialist health and life sciences team.